These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 17101640)

  • 1. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Polonsky T; Mazzone T; Davidson M
    Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
    Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone vs glimepiride and carotid intima-media thickness.
    Giugliano D; Esposito K
    JAMA; 2007 Mar; 297(12):1315-6; author reply 1316-7. PubMed ID: 17392236
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
    Davidson MH; Beam CA; Haffner S; Perez A; D'Agostino R; Mazzone T
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1873-6. PubMed ID: 20576945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone vs glimepiride and carotid intima-media thickness.
    Kida Y; Sato T
    JAMA; 2007 Mar; 297(12):1316; author reply 1316-7. PubMed ID: 17392237
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.
    Zheng L; Hodis HN; Buchanan TA; Li Y; Mack WJ
    Am J Cardiol; 2007 Apr; 99(7):956-60. PubMed ID: 17398191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
    Pfützner A; Marx N; Lübben G; Langenfeld M; Walcher D; Konrad T; Forst T
    J Am Coll Cardiol; 2005 Jun; 45(12):1925-31. PubMed ID: 15963388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.